112398-08-0

Basic information

• Product Name: DANOFLOXACIN
• Synonyms: DANOFLOXACIN;DANOFLOXACIN BASE;ADVOCIN(R);Danofloxacin, Vetranal;DANOFLOXACIN, 98.5%;advocin;Danofloxacin,Advocin;3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(1S,4S)-5-Methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-4-oxo-
• CAS NO: 112398-08-0
• Molecular Formula: C19H20FN3O3
• Molecular Weight: 357.38
• Mol File: 112398-08-0.mol
• Article Data: 2

Chemical Properties

• Melting Point: 268-272 C
• Boiling Point: 569.3°Cat760mmHg
• Flash Point: 298.1°C
• Appearance: /
• Density: 1.485g/cm³
• Vapor Pressure: 8.41E-14mmHg at 25°C
• Refractive Index: 1.679
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Aqueous Base (Slightly), Chloroform (Very Slightly, Heated), Water (Slightly)
• PKA: 6.43±0.41(Predicted)
• Water Solubility: Soluble in water, acetic acid and DMSO
• CAS DataBase Reference: DANOFLOXACIN(CAS DataBase Reference)
• NIST Chemistry Reference: DANOFLOXACIN(112398-08-0)
• EPA Substance Registry System: DANOFLOXACIN(112398-08-0)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 22-24/25-37/39-36-26
• WGK Germany: 3
• Hazardous Substances Data: 112398-08-0(Hazardous Substances Data)

Usage

Description

Danofloxacin is a synthetic, broad-spectrum fluoroquinolone antibiotic with potent antibacterial and antimycoplasmal properties. It is characterized by its ability to inhibit bacterial DNA synthesis and replication, leading to the disruption of bacterial cell function and ultimately cell death. Danofloxacin is particularly effective against a wide range of gram-negative and gram-positive bacteria, as well as mycoplasma species, making it a valuable asset in veterinary medicine for the treatment of various bacterial infections.
Used in Veterinary Medicine:
Danofloxacin is used as an antibacterial and antimycoplasmal drug for the treatment of bacterial infections in animals. Its broad-spectrum activity allows it to target a variety of bacterial pathogens, making it a versatile choice for veterinary practitioners. The drug is effective in treating respiratory infections, urinary tract infections, skin infections, and other bacterial diseases in a range of animal species, including cattle, pigs, poultry, and companion animals.
Used in Companion Animal Care:
In the companion animal industry, Danofloxacin is used as a treatment for various bacterial infections in pets such as dogs and cats. It is particularly useful for treating respiratory infections caused by bacteria like Bordetella bronchiseptica and Mycoplasma species, which are common in these animals. The use of Danofloxacin helps to reduce the severity and duration of these infections, improving the overall health and well-being of companion animals.
Used in Livestock Production:
In the livestock industry, Danofloxacin is used as a prophylactic and therapeutic agent to prevent and treat bacterial infections in animals such as cattle and pigs. Its broad-spectrum activity makes it an effective tool for controlling infections that can lead to reduced productivity and increased mortality rates in these populations. By incorporating Danofloxacin into their treatment protocols, livestock producers can help to maintain the health of their animals and ensure a stable food supply.
Used in Poultry Health Management:
In the poultry industry, Danofloxacin is used to manage bacterial infections that can impact the health and productivity of birds. It is particularly useful in treating respiratory infections, which can be a significant issue in large-scale poultry operations. By using Danofloxacin as part of a comprehensive health management plan, poultry producers can help to maintain the overall health of their flocks and protect their investment.

InChI:InChI=1/C19H20FN3O3/c1-21-7-12-4-11(21)8-22(12)17-6-16-13(5-15(17)20)18(24)14(19(25)26)9-23(16)10-2-3-10/h5-6,9-12H,2-4,7-8H2,1H3,(H,25,26)/t11-,12-/m0/s1

Upstream product

• 93107-30-3 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
• 52321-26-3 (1S,4S)-5-methyl-2,5-diazabicyclo<2.2.1>heptane dihydrochloride 

Related news

Technetium-labeled DANOFLOXACIN (cas 112398-08-0) complex as a model for infection imaging07/20/2019

Danofloxacin, a fluoroquinolone derivative antibiotic, was synthesized, successfully labeled with technetium-99m and formulated for the development of a potential diagnostic imaging agent of the bacterial infection and inflammation with higher efficiency than that of the commercially available 9...detailed

The regulation effects of DANOFLOXACIN (cas 112398-08-0) on pig immune stress induced by LPS07/21/2019

Danofloxacin (DAN) is one of the Fluoroquinolone drugs (FQs) that has been widely used in the control and prevention of bacterial infectious disease in animal production. Most of the FQs have an obvious protective effect against lipopolysaccharide (LPS) induced Immune stress. However, the effect...detailed

DANOFLOXACIN (cas 112398-08-0) depletion from muscle plus skin tissue of European sea bass (Dicentrarchus labrax) fed DANOFLOXACIN (cas 112398-08-0) mesylate medicated feed in seawater at 16 °C and 27 °C07/19/2019

Residue depletion of danofloxacin was investigated in European sea bass after a multiple (5 days) in-feed administration of danofloxacin mesylate (10 mg/kg bw per day) under experimental field conditions at water temperature of 16 °C and 27 °C. Ten fish per sampling point were examined during ...detailed

Relevant articles and documents

Synthesis and structure-activity relationships of 7- diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine

A series of novel 6-fluoro-7-diazabicycloalkylquinolonecarboxylic acids substituted with various C8 (H, F, Cl, N) and N1 (ethyl, cyclopropyl, vinyl, 2-fluoroethyl, 4-fluorophenyl, 2,4-difluorophenyl) substituents, as well as, 9-fluoro-10-diazabicycloalkylpyridobenzoxazinecarboxylic acids, were prepared and evaluated for antibacterial activity against a range of important veterinary pathogenic bacteria. The diazabicycloalkyl side chains investigated at the 7-position (benzoxazine 10-position) include (1S,4S)-5- methyl-2,5-diazabicyclo[2.2.1]heptane (2), (1S,4S)-2,5- diazabicyclo[2.2.1]heptane (3), (1R,4R)-5-methyl-2,5- diazabicyclo[2.2.1]heptane (4), 8-methyl-3,8-diazabicyclo[3.2.1]octane (5), 9-methyl-3,9-diazabicyclo[4.2.1]nonane (6), 1,4-diazabicyclo[3.2.2]nonane (7), 1,4-diazabicyclo[3.3.1]nonane (8), and 9-methyl-3,9- diazabicyclo[3.3.1]nonane (9). Among these side chains, in vitro potency was not highly variable; other properties therefore proved more critical to the selection of possible development candidates. However, the relative potencies observed for several of these compounds in mouse, swine, and cattle infection models correlated well with those seen in vitro. A combination of the N1 cyclopropyl group and the C7 (1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2- yl appendage conferred the best overall antibacterial, physiochemical, and pharmacodynamic properties. Hence, danofloxacin (Advocin, 2c) (originally CP- 76,136, 1-cyclopropyl-6-fluoro-7-[(1S,4S)-5-methyl-2,5- diazabicyclo[2.2.1]hept-2-yl]-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid) was selected as a candidate for development as a therapeutic antibacterial agent for veterinary medicine.